Breaking News

Thermo Fisher Scientific Signs CDx Agreement with Hengrui Therapeutics

Will leverage the Oncomine Precision Assay to identify non-small cell lung cancer patients who may benefit from pyrotinib.

By: Contract Pharma

Contract Pharma Staff

Thermo Fisher Scientific has signed a companion diagnostic (CDx) agreement with Hengrui Therapeutics Inc. (HTI), a U.S. subsidiary of Chinese pharmaceutical company Jiangsu Hengrui Medicine Co. Ltd. (JHM), to develop a CDx that will leverage the Oncomine Precision Assay. The CDx will be used to identify patients with HER2-mutated non-small cell lung cancer (NSCLC) who may benefit from the drug pyrotinib – ultimately helping to broaden participation in clinical trials.   HER2 mutations are presen...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters